Core Viewpoint - Moderna is facing a $5 billion patent-infringement lawsuit regarding its COVID-19 vaccine, Spikevax, which allegedly infringes on lipid nanoparticle technology patented by Genevant Sciences and Arbutus Biopharma [1]. Legal Proceedings - U.S. District Judge Joshua D. Wolson denied Moderna's request for summary judgment, allowing the jury to decide on the patent infringement claims [1]. - The judge emphasized the importance of patent law, stating that copying inventions is not permissible, even with expedited vaccine development under "Operation Warp Speed" [2]. Technical Aspects of the Case - The lawsuit centers on the delivery mechanism of the vaccine, specifically how Messenger RNA (mRNA) is protected by lipid nanoparticles, which are claimed to be patented by the plaintiffs [3]. - Arbutus Biopharma asserts that their research involved identifying specific "molar ratios" of lipids necessary for the vaccine's safety and efficacy [3]. Government Immunity Defense - Moderna's defense strategy included invoking section 1498, which protects government contractors from patent infringement lawsuits, arguing that the vaccine was developed under a federal program [4]. - However, the judge ruled that section 1498 applies only if the product was intended for the government itself, not the general public, which could expose Moderna to $5 billion in damages [5]. Patent Validity and Infringement - The jury will also evaluate the scientific validity of the patent claims and the concept of "literal infringement," with the judge allowing certain technical requests regarding how patent infringement can be established [6].

Company Performance - Novartis (NVS) has returned approximately 26.2% since the beginning of the calendar year, outperforming the Medical sector, which has returned an average of -2.6% [4] - The Zacks Consensus Estimate for Novartis' full-year earnings has increased by 1.9% over the past 90 days, indicating improving analyst sentiment and a positive earnings outlook [3] Industry Context - Novartis is part of the Large Cap Pharmaceuticals industry, which consists of 10 companies and currently ranks 52 in the Zacks Industry Rank. The average performance of stocks in this group is 0% year-to-date, highlighting Novartis' superior performance [5] - In comparison, Arbutus Biopharma, another outperforming stock in the Medical sector, has seen a year-to-date increase of 34.6% and is part of the Medical - Biomedical and Genetics industry, which has a ranking of 97 and has moved up by 3.1% since the start of the year [4][6]

Company Performance - Aquestive Therapeutics (AQST) has returned approximately 12.6% year-to-date, outperforming the Medical sector, which has returned an average of -4.9% [4] - The Zacks Consensus Estimate for AQST's full-year earnings has increased by 0.5% over the past 90 days, indicating improving analyst sentiment [3] Industry Ranking - Aquestive Therapeutics is part of the Medical - Drugs industry, which consists of 153 companies and currently ranks 84 in the Zacks Industry Rank [5] - The average return for the Medical - Drugs industry so far this year is 8.3%, suggesting that AQST is performing better than its industry peers [5] Sector Overview - The Medical sector includes 978 individual stocks and is currently ranked 8 in the Zacks Sector Rank, which evaluates 16 different sector groups [2] - Arbutus Biopharma (ABUS), another stock in the Medical sector, has returned 3.1% year-to-date and has a Zacks Rank of 2 (Buy) [4][5]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Editas Medicine (EDIT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Editas Medicine is one of 1001 individual stocks in the Medical sector. Collectiv ...

Core Insights - The webinar focuses on strategic time management for Investor Relations (IR) teams, addressing the increasing pressures from new regulations, rising ESG expectations, and direct engagement with investors [1][4]. Group 1: Webinar Details - The live session is scheduled for Tuesday, May 13, 2025, at 11:00 am ET [3]. - Registration details are provided through a link [3]. Group 2: Key Learning Outcomes - Participants will learn how leading IROs allocate their time across various activities [5]. - The session will cover effective team structuring for success [5]. - Practical tips for maintaining focus during critical events like investor days will be shared [5]. Group 3: Speaker Profiles - Lisa Caperelli, former VP of Investor Relations at Arbutus Biopharma, has over 20 years of experience in IR communications strategies [5]. - Erik Carlson, COO of Notified, has extensive expertise in private equity and business transformation, advising on over 100 deals [5]. - Katie Keita, IR Lead at Kneat Solutions, has over 20 years of IR experience in tech companies and previously built Shopify's IR program [5]. - Steve Wade, Head of Content at IR Impact, focuses on IR, governance, and sustainability, curating events and digital content [5].

Core Insights - Arbutus Biopharma Corporation announced the acceptance of five abstracts for presentation at the EASL Congress 2025, including one late-breaker, highlighting the company's ongoing research in hepatitis B treatments [2][9]. Group 1: Abstract Presentations - Five abstracts will be presented in the Viral Hepatitis B and D session on May 8, 2025, showcasing new therapies and strategies [3]. - The late-breaker abstract will focus on the antiviral efficacy and safety of imdusiran followed by VTP-300 in chronic hepatitis B subjects [9]. Group 2: Key Findings from Abstracts - Abstract 1768 discusses the factors associated with functional cure in chronic hepatitis B subjects, indicating that baseline HBsAg levels are significant [4]. - Abstract 2043 reveals that rapid HBV RNA decline during treatment with imdusiran and interferon is linked to HBsAg seroclearance [6]. - Abstract 1990 presents the pharmacokinetics and pharmacodynamics of AB-101, showing it to be safe and well-tolerated with dose-responsive increases in PD-L1 receptor occupancy [7]. - Abstract 1978 indicates that AB-101 is well-tolerated in both healthy and chronic hepatitis B subjects, with ongoing dosing studies [8]. Group 3: Product Information - Imdusiran is an RNAi therapeutic designed to reduce HBV viral proteins, showing promising results in Phase 2a trials for achieving functional cure rates [10]. - AB-101 is an oral PD-L1 inhibitor currently in Phase 1a/1b trials, aimed at reactivating exhausted HBV-specific T-cells [11]. Group 4: Industry Context - Chronic hepatitis B infection affects over 250 million people globally, representing a significant unmet medical need, with approximately 1.1 million deaths annually from related complications [12].